Table 1.

Clinical characteristics of critically ill COVID‐19‐infected patients with putative invasive pulmonary aspergillosis

	Patient 1	Patient 2	Patient 3	Patient 4
Age (y)	82	79	77	77
Gender	Male	Male	Male	Male
Comorbid conditions
Hypertension	No	Yes	No	No
Diabetes	No	No	No	Yes
Coronary artery disease	No	Yes	No	No
Chronic obstructive pulmonary disease	Yes	No	No	No
History of cerebrovascular accident	No	Yes	No	No
History of cancer	Yes	Yes	No	No
Dementia	No	No	No	No
Timing of positive culture for Aspergillus fumigatus (hospital day)	Day 15 and 20	Day 7, 10, and 16	Day 10 and 14	Day 10
Clinical features at Aspergillus isolation
Fever	No	No	Yes	No
Respiratory status at Aspergillus isolation	IMV	IMV	IMV	IMV
New radiographic abnormalities on chest CT or X‐ray	Worsening infiltrates	Opacities with dense consolidations	Cavitary pneumonia	Diffuse interstitial and patchy hazy opacities
White blood cell count (103/μL)	32.9	21.1	20.1	20.2
Platelet count (103/μL)	376	146	420	123
Procalcitonin (ng/mL)	0.16	0.30	3.30	9.34
Lactic acid (mmol/L)	1.0	3.6	1.6	3.7
Total bilirubin (mg/dL)	2.4	1.1	1.4	2.9
Serum creatinine (mg/dL)	2.6	3.1	1.5	4.1
Serum galactomannan	NA	0.71	Negative	Negative
Vasopressor support	Yes	Yes	Yes	Yes
Inpatient medications
Glucocorticoids
Cumulative dose in prednisone equivalent (mg)	932	1000	870	87
Starting date (hospital day)	Day 8	Day 2	Day 2	Day 10
Duration (d)	10	10	12	3
Tocilizumab	No	Yes	No	No
Antibiotics	Cefepime + Vancomycin	Cefepime + Vancomycin	Meropenem + Vancomycin	Cefepime + Vancomycin
Antifungal therapy	Voriconazole	Voriconazole	Voriconazole	Caspofungin

Abbreviations: IMV, invasive mechanical ventilation; NA, not available.